What role do combinations of interferon and targeted agents play in the first-line therapy of metastatic renal cell carcinoma?

Clinical Genitourinary Cancer

Volumn 6, Issue SUPPLEMENT 1, 2008, Pages

  Bukowski, Ronald M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bevacizumab; Cytokines; Interferon ; Mammalian target of rapamycin; Temsirolimus

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; FLUOROURACIL; INTERFERON; INTERLEUKIN 2; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RETINOIC ACID; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VINBLASTINE;

ALOPECIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG MECHANISM; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNOMODULATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUTROPENIA; PROTEINURIA; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TUMOR REGRESSION; VOMITING; WEIGHT REDUCTION;

EID: 70349306437     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2008.s.003     Document Type: Article

References (61)

1. Quesada JR, Swanson DA, Trindale A, et al. Renal cell carcinoma antitumor effects of leukocyte interferon. Cancer Res 1983, 43:940-7.
2. (Pubitemid 34595504) Kubo S, Nishiguchi S, Hirohashi K, et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418-22
3. Uzzo RG, Rayman P, Novick AC, et al. Molecular Mechanisms of Immune Dysfunction in Renal Cell Carcinoma. In: Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical Management. Eds: Bukowski RM, Novick AC. Totowa, New Jersey: Humana Press, 2000. pp 63-78.
4. (Pubitemid 34240546) Shou J, Soriano R, Hayward SW, et al. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci U S A 2002;99:2830-5.
5. Reu FJ, Leaman DW, Maitra RR, et al. Expression of RASSFIA, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res 2006;66:2785-93.
6. (Pubitemid 12174452) Branca AA, Baglioni C. Evidence that types I and II interferons have different receptors. Nature 1981;294:768-70.
7. (Pubitemid 15067117) Merlin G, Falcoff E, Aguet M. 125I-labelled human interferons alpha, beta and gamma: comparative receptor-binding data. J Gen Virol 1985;66:1149-52.
8. Ruzicka FJ, Schmid SM, Groveman DS, et al. Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro. Cancer Res 1987;47:4582-9.
9. Domanski P, Witte M, Kellum M, et al. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem 1995;270:21606-11.
10. (Pubitemid 34246317) Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002;285:1-24.
11. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
12. (Pubitemid 43208827) Valentino L, Pierre J. JAK-STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006;71:713-21.
13. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-7.
14. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumorand lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-65.
15. (Pubitemid 28099496) Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808-14.
16. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
17. (Pubitemid 36432418) von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437-48.
18. von Hoegen P. Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol Lett 1995;47:157-62.
19. (Pubitemid 9213546) Zarling JM, Eskra L, Borden EC, et al. Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol 1979;123:63-70.
20. (Pubitemid 28387618) Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161:1947-53.
21. (Pubitemid 28183368) Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998;16:323-58.
22. Banerjee D, Chadalavada RS, Bourdon V, et al. Transcriptional program associated with IFN-alpha response of renal cell carcinoma. J Interferon Cytokine Res 2006;26:156-70.
23. (Pubitemid 14211183) DeKernion JB, Sarna JB, Figlin R, et al. The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 1983;130:1063-66.
24. Bukowski RM, Novick AC. Clinical practice guidelines: renal cell carcinoma. Cleve Clin J Med 1997; 64:S1-48.
25. (Pubitemid 29415245) Pyrhonen S, Salminen E, Ruuru M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-67.
26. Medical Research Council Renal Cancer Collaborators. Interferon α and sur vival in metastatic renal cell carcinoma: Early results of randomized trial. Lancet 1999;353:14-7
27. Gore ME. Interferon-α (IFN), interleukin-2 (IL-2), and 5-fluorouracil (5-FU) vs IFN alone in patients with metastatic renal cell carcinoma (mRCC) : Results of the randomized MRC/EORTC RE043 trial. J Clin Oncol 2008;26(15 suppl):259s (Abstract 5039).
28. (Pubitemid 30644121) Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2972-80.
29. (Pubitemid 28216581) Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant interferon alfa-2a, or both in metastatic renal cell carcinoma. Groupe Francaise d-Immunotherapie. N Engl J Med 1998;338:1272-8.
30. (Pubitemid 44665661) Tannir NM, Cohen L, Wang X, et al. Improved tolerability and quality of life with maintained efficacy using twice daily low-dose Interferon-alpha-2b: results of a randomized phase II trial of low dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006: 107:2254-61.
31. Flannigan RC, Salmon E, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell carcinoma. N Engl J Med 2001;345:1655-9.
32. (Pubitemid 32913522) Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferonalfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomized trial. Lancet 2001;358:966-70.
33. Coppin C, Porzsolt F, Kumpf J, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000; 110:CD001425.
34. (Pubitemid 35050837) Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I/II study. J Clin Oncol 2002;20:3841-9.
35. (Pubitemid 29368255) Motzer RJ, Mazumadar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
36. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41.
37. (Pubitemid 350174932) Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, Interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110:2468-77.
38. (Pubitemid 46089672) Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
39. Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007;25(18 suppl):241s (Abstract 5025).
40. (Pubitemid 350296300) Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab in combination with interferon alfa-2a as first-line therapy for metastatic renal-cell carcinoma. Lancet 2007;370:2103-11.
41. (Pubitemid 46089672) Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
42. (Pubitemid 27441066) Presta LG, Chen H, O-Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
43. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536-41.
44. (Pubitemid 36910021) Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
45. Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Florida. Abstract 350.
46. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;19:1470-6.
47. (Pubitemid 39331023) Wilhelm SM, Carte C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
48. (Pubitemid 46089673) Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
49. (Pubitemid 46952949) Escudier B, Lassau N, Angevin E, et al. Phase 1 trial of sorafenib in combination with IFN alpha-2b in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13:1801-9.
50. Ryan CW, Goldman BH, Lara PN, et al. Sorafenib with interferon alfa-2b as first line Treatment of Advanced Renasl Cell Carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007;25:3296-301.
51. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon Alfa-2b as first or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25:3288-95.
52. Jonasch E, Corn P, Ashe RG, et al. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 2007;25(18 suppl):260s (Abstract 5104).
53. Tannir NM, Zurita AJ, Heymach J V, et al. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 2008;26(15 suppl):272s (Abstract 5093).
54. Bracarda S, Porta C, Boni C, et al. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-á2a (IFN) in metastatic renal cell carcinoma (RAPSODY) : GOIRC Study 0681. Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Florida. Abstract 357.
55. Kondagunta GV, Hudes GR, Figlin R, et al. Sunitinib malate (SU) plus Interferon (IFN) in first line metastatic renal cell carcinoma (mRCC) : Results of a dose finding study. J Clin Oncol 2007;25(18 suppl):260s (Abstract 5101).
56. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48.
57. (Pubitemid 43927103) Del Bufalo D, Cuffrede L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66:5549-54.
58. (Pubitemid 32803018) Podsypasnina K, Lee RT, Politis C, et al. An inhibitor of m TOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/-mice. Proc Natl Acad Sci U S A 2001;98:10320-5.
59. (Pubitemid 41103603) Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18.
60. Gibbons JJ. CCI-779 potentiates the inhibitory effect of the anti-angiogenesis drug interferon-alpha on the growth of a human renal cell carcinoma in nude mice. RPT-49843. Pearl River, NY, Wyeth Research, 2006.
61. Motzer RJ, Hudes GR, Curti BD, et al. Temsirolimus plus interferon alfa phase I trial in patients with advanced renal cell carcinoma. J Clin Oncol 2007;25:3958-64.